The neurons in question produce acetylcholine, a chemical messenger that is critical for a range of functions including sleep, cognition and movement. Their gradual loss is linked to some of Parkinson’s most disabling and treatment-resistant symptoms: problems with gait and balance, disturbed sleep, cognitive decline and, in some people, psychosis. While much of the public and scientific attention on Parkinson’s has centred on dopamine-producing neurons in the midbrain, which underlie the condition’s characteristic tremor, rigidity and slowness of movement, this study shifts focus to a brainstem population whose decline shapes the broader, often harder-to-treat burden of the illness.

To interrogate these cells, the team used advanced single-cell mitochondrial DNA sequencing combined with computational analysis, examining individual neurons from brain tissue generously donated by people who had lived with Parkinson’s disease, alongside tissue from healthy controls. Rather than averaging signals across thousands of cells, the single-cell approach allowed the researchers to read out the mitochondrial genome of each neuron separately, revealing the extent and pattern of damage cell by cell. Dr Ilse Pienaar of the University of Birmingham, a senior author of the study, noted that this is the first time single-cell mitochondrial genetic sequencing has been applied to these specific brainstem neurons in people with Parkinson’s disease, and that studying individual neurons has allowed the team to see, in unprecedented detail, the mitochondrial changes associated with their vulnerability.

What the sequencing revealed was striking. The affected neurons carried extensive large-scale deletions in their mitochondrial DNA, and these deletions were particularly concentrated within a stretch of the mitochondrial genome known as the major arc. This region is densely populated with genes that are essential for producing energy in cells, so removing chunks of it strikes directly at the machinery that keeps a neuron powered. Mitochondria are often described as the powerhouses of the cell, and damage to their DNA can interfere with their ability to generate the energy that neurons need, potentially leaving these cells less able to cope with the relentless electrical and metabolic demands placed on them across a human lifetime.

The biological logic of this vulnerability is compelling. Neurons are among the most energy-hungry cells in the body, and brainstem cholinergic neurons must sustain long projections and continuous signalling to regulate sleep-wake cycles, attention and motor control. If their mitochondrial genomes accumulate deletions in the very region that encodes core components of the energy-production system, the resulting power deficit could compound over time, gradually eroding the cell’s capacity to survive. The new findings therefore provide a mechanistic account of why these acetylcholine-producing neurons may be particularly susceptible to degeneration in Parkinson’s disease, complementing decades of work on dopaminergic cell loss.

Yet the study is not simply a catalogue of damage. Despite the extensive mitochondrial DNA lesions, the researchers found evidence that the neurons may be mounting an active protective response. The affected cells showed increased levels of PINK1, a gene central to mitochondrial quality control. PINK1 helps cells identify mitochondria that have become damaged and target them for removal, a process that clears dysfunctional power units from the network and helps maintain a population of healthy mitochondria capable of sustaining energy production. In other words, even as the mitochondrial genomes of these neurons crumbled, the cells appeared to be ramping up the molecular machinery that weeds out the worst-affected organelles.

Perhaps the most intriguing observation concerns individual variation. Higher levels of PINK1 were particularly evident in neurons from people who had survived longer after their Parkinson’s diagnosis. This pattern raises the possibility that a stronger mitochondrial quality-control response helps some neurons withstand damage for longer, effectively buying time and preserving function in the face of accumulating genetic injury. If confirmed, the finding would suggest that the trajectory of Parkinson’s disease is shaped not only by the forces that damage neurons but also by the variable vigour of the brain’s own defences against that damage.

Dr Joanna Elson of Newcastle University, a senior author of the study, described the results as revealing an extraordinary resilience within these vulnerable neurons. Although the team observed extensive mitochondrial DNA damage, the cells appear to mount a protective response through increased PINK1 expression, likely as an attempt to maintain healthy mitochondria and preserve energy production. She added that understanding why this response appears to be more effective in some individuals than others could open new avenues for therapies aimed at supporting the brain’s own protective mechanisms. Dr Pienaar similarly emphasised that the findings point towards biological pathways that could potentially be harnessed therapeutically, and that strengthening the mechanisms which maintain mitochondrial health could ultimately help slow disease progression and improve quality of life for people living with Parkinson’s.

The therapeutic implications are considerable. PINK1 has long been known to the Parkinson’s field because mutations in the gene cause early-onset, inherited forms of the disease, placing it at the heart of the cellular pathway that surveys mitochondrial health and dispatches damaged organelles. The new data suggest that this same pathway is active in the vulnerable brainstem neurons of people with sporadic Parkinson’s, and that its activity correlates with survival after diagnosis. That correlation makes mitochondrial quality control an attractive target for drug development: if researchers can identify why the response is more effective in some patients and find ways to amplify it in others, treatments might be developed that enhance the brain’s natural protective mechanisms rather than simply replacing lost neurotransmitters.

The researchers hope the findings will catalyse further studies of mitochondrial quality-control pathways as potential therapeutic targets in Parkinson’s disease, and that understanding how some neurons withstand damage could ultimately inform treatments that bolster these defences across the brain. For a condition that affects millions worldwide and for which current therapies address symptoms rather than halt progression, the demonstration that single-cell sequencing can expose both the vulnerabilities and the resilience of individual human neurons marks a methodological and conceptual advance. It reframes Parkinson’s disease, in part, as a struggle between mitochondrial damage and cellular self-repair, one in which the outcome may depend on how well each neuron can keep its power supply intact.

Subject of Research: Single-cell mitochondrial DNA sequencing of vulnerable brainstem cholinergic neurons in Parkinson's disease

Article Title: First study to sequence mitochondrial DNA from individual vulnerable brainstem neurons in Parkinson’s disease

Article References: First study to sequence mitochondrial DNA from individual vulnerable brainstem neurons in Parkinson’s disease. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Parkinson's disease, mitochondrial DNA, single-cell sequencing, brainstem neurons, PINK1, cholinergic neurons, mitochondrial quality control, neurodegeneration, major arc deletions, Brain journal, University of Birmingham, Newcastle University